Raymedica^® Releases 1^st of a 4-Book Series on “Nucleus Arthroplasty™ in Spinal Care.”

MINNEAPOLIS, September 25 - Raymedica, a medical device company located in Minneapolis, Minnesota, announced that the first of a four-book series entitled, “Nucleus Arthroplasty in Spinal Care” will be released at the North American Spine Society (NASS) 21st Annual Meeting being held in Seattle, WA, September 27-29, 2006. This complimentary publication will be made available at Raymedica Booth # 413.
 
Raymedica has jointly produced and published “Nucleus Arthroplasty in Spinal Care” with noted physician authors: Dr. med. univ. Rudolph Bertagnoli, Reginald J. Davis, MD, FACS, Federico P. Girardi, MD and Alexander R. Vaccaro, MD. This resource, which is referred to as “NASC Book 1,” lays the foundation for the remaining series by providing expert counsel on key subject matter, which explores nucleus arthroplasty and how it will impact non-fusion spine surgery.
 
“The release of the “Nucleus Arthroplasty in Spinal Care” series marks a further step forward for what is already a very successful year for Raymedica,” said John J. Viscogliosi, Chairman and CEO of Raymedica. “The noted physician authors, whose initiative it was to develop this series, are to be congratulated for all their hard work in seeing the project from inception to release. This publication provides spine surgeons and our industry colleagues with unparalleled access to the emerging technology of nucleus arthroplasty.”

The series of publications is expected to be exceedingly popular as more and more noted authors are submitting monographs for upcoming issues in the series, and more readers are accessing the completed works. These publications are free and available for download at www.nucleusarthroplasty.com.

About Raymedica, LLC.
Raymedica, LLC, based in Minneapolis, Minnesota, is the Pioneer in Nucleus Arthroplasty having developed the world’s first nucleus replacement device in 1996. Raymedica develops, manufactures and markets medical device systems designed to treat patients with degenerative disc disease that have been unresponsive to non-surgical treatment. Raymedica’s products are currently available in many countries worldwide, but are limited to investigational use only in the United States. For more information, visit the Company’s website at http://www.raymedica.com.